Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jun;41(6):1215–1219. doi: 10.1128/aac.41.6.1215

Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.

S Keil 1, B Wiedemann 1
PMCID: PMC163889  PMID: 9174173

Abstract

In an in vitro dynamic model we compared the antimicrobial effects of two carbapenems, imipenem (MIC, 1 microg/ml) and meropenem (MIC, 0.25 microg/ml) on Pseudomonas aeruginosa. The antibiotics were administered either as short-time infusions once or three times a day or as continuous infusions with steady-state levels ranging from 0.5 to 20 microg/ml. From the resulting kill curves the period of time until the onset of bacterial death (dt), the rate constant of bacterial death (ka), the maximal reduction of CFU (mr), and the period of time until bacterial regrowth occurred (tr) were determined. Additionally, the occurrence of bacterial resistance during the simulations (rq) and the postantibiotic effect (PAE) were recorded. For both investigated carbapenems no significant difference in dt, ka, mr, and PAE values between the short-time infusions and continuous infusions with steady-state levels above 2 microg/ml could be detected. The tr was longest with continuous infusions of over approximately 24 h, corresponding to steady-state levels of 3 microg/ml for imipenem and 2.5 microg/ml for meropenem. An increase in MIC was observed only during continuous infusions with steady-state levels below 2 microg/ml. Independent of the chosen method of application and despite the lower MIC of meropenem, imipenem was slightly more effective than meropenem.

Full Text

The Full Text of this article is available as a PDF (182.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakker-Woudenberg I. A., van den Berg J. C., Fontijne P., Michel M. F. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol. 1984 Apr;3(2):131–135. doi: 10.1007/BF02014330. [DOI] [PubMed] [Google Scholar]
  2. Christensson B. A., Nilsson-Ehle I., Hutchison M., Haworth S. J., Oqvist B., Norrby S. R. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992 Jul;36(7):1532–1537. doi: 10.1128/aac.36.7.1532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Craig W. A., Ebert S. C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992 Dec;36(12):2577–2583. doi: 10.1128/aac.36.12.2577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Daenen S., Erjavec Z., Uges D. R., De Vries-Hospers H. G., De Jonge P., Halie M. R. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis. 1995 Mar;14(3):188–192. doi: 10.1007/BF02310354. [DOI] [PubMed] [Google Scholar]
  5. David T. J., Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989 Jun 24;1(8652):1454–1455. doi: 10.1016/s0140-6736(89)90164-5. [DOI] [PubMed] [Google Scholar]
  6. Drusano G. L., Standiford H. C., Bustamante C. I., Forrest A., Rivera G., Tatem B., Schimpff S. C. The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Eur J Clin Microbiol. 1984 Oct;3(5):468–470. doi: 10.1007/BF02017377. [DOI] [PubMed] [Google Scholar]
  7. Drusano G. L., Standiford H. C., Bustamante C., Forrest A., Rivera G., Leslie J., Tatem B., Delaportas D., MacGregor R. R., Schimpff S. C. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother. 1984 Nov;26(5):715–721. doi: 10.1128/aac.26.5.715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Flückiger U., Segessenmann C., Gerber A. U. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother. 1991 Sep;35(9):1905–1910. doi: 10.1128/aac.35.9.1905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kahan F. M., Kropp H., Sundelof J. G., Birnbaum J. Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):1–35. doi: 10.1093/jac/12.suppl_d.1. [DOI] [PubMed] [Google Scholar]
  10. Keil S., Wiedemann B. Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models. Antimicrob Agents Chemother. 1995 May;39(5):1054–1058. doi: 10.1128/aac.39.5.1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mouton J. W., den Hollander J. G. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994 May;38(5):931–936. doi: 10.1128/aac.38.5.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Odenholt-Tornqvist I. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J Antimicrob Chemother. 1993 Jun;31(6):881–892. doi: 10.1093/jac/31.6.881. [DOI] [PubMed] [Google Scholar]
  13. Paradis D., Vallée F., Allard S., Bisson C., Daviau N., Drapeau C., Auger F., LeBel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother. 1992 Oct;36(10):2085–2092. doi: 10.1128/aac.36.10.2085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Roosendaal R., Bakker-Woudenberg I. A., van den Berghe-van Raffe M., Michel M. F. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother. 1986 Sep;30(3):403–408. doi: 10.1128/aac.30.3.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Signs S. A., Tan J. S., Salstrom S. J., File T. M. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. Antimicrob Agents Chemother. 1992 Jul;36(7):1400–1403. doi: 10.1128/aac.36.7.1400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Thauvin C., Eliopoulos G. M., Willey S., Wennersten C., Moellering R. C., Jr Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987 Feb;31(2):139–143. doi: 10.1128/aac.31.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wise R., Donovan I. A., Lockley M. R., Drumm J., Andrews J. M. The pharmacokinetics and tissue penetration of imipenem. J Antimicrob Chemother. 1986 Dec;18 (Suppl E):93–101. doi: 10.1093/jac/18.supplement_e.93. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES